COPD landmark trial UPLIFT proves tiotropium sustains lung function
improvements over four years and
improves survival rate

Results of the UPLIFT trial, presented at the European Respiratory Society (ERS) Annual Congress on October 5, demonstrated that tiotropium (SPIRIVA) administered to Chronic Obstructive Pulmonary Disease (COPD) patients, showed sustained improvements in lung function for up to 4 years (p<0.001), although
it did not alter the rate of decline in lung function. The landmark study also reaffirmed the favourable safety profile of tiotropium.

“The results from UPLIFT are good news, especially for primary care physicians who are usually the first medical contact a patient has once they decide to seek treatment. UPLIFT provides the confidence that treatment benefits of tiotropium are sustained long-term, and COPD patients can lead more active lives for longer,”
said Dr. Anders Østrem, MD, Specialist in Family Medicine, Oslo, Norway and past President of International Primary Care Respiratory Group.